<DOC>
	<DOC>NCT00154297</DOC>
	<brief_summary>The purpose of this study is to evaluate if the delayed administration of everolimus could reduce the everolimus associated "anti-proliferative complications" (e.g. wound healing disorder) while maintaining efficacy, when compared to the immediate administration of everolimus in de novo renal transplant patients.</brief_summary>
	<brief_title>Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Recipients of cadaveric kidney transplants Patients at risk of DGF defined as one or more of the following: Donor age &gt; 55 years Cold ischemic time (CIT) â‰¥ 24 hours but &lt; 40 hours Second or subsequent renal transplantation Patients who have received an investigational drug within 4 weeks of baseline period Patients who are recipients of multiple organ transplants, including more than one kidney, or previous transplant with any organ other than kidney Patients with body mass index (BMI) &gt; 32 kg/m2 Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Renal transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>immunosuppressants</keyword>
	<keyword>wound-healing</keyword>
</DOC>